Sanofi is changing the organizational structure of two of its Global Business Units (GBU) in an effort to provide greater focus on its operations in mature markets and across emerging markets.
The company will create a new Primary Care GBU that combines the product portfolios of Sanofi’s existing Diabetes and Cardiovascular (DCV) GBU with Established Products, which are currently part of the General Medicines & Emerging Markets (GEM) GBU.  The new Primary Care unit will focus exclusively on mature markets.


 
Dieter Weinand has been appointed executive vice president to lead the new Primary Care business unit, effective November 1^st. Mr. Weinand will report directly to Sanofi chief executive officer Olivier Brandicourt and will become a member of the Executive Committee. He will be based in Bridgewater, NJ. Also, Stefan Oelrich, currently head of the DCV GBU, has decided to leave Sanofi and will join Bayer AG as a member of the Board of Management.

 
“Dieter is a seasoned professional with significant experience in the pharmaceutical sector, having successfully launched and marketed some of the most innovative medicines in the last few years. He has a proven track record in change management and helping challenged businesses reach their full potential,” said Dr. Brandicourt. “As we welcome Dieter into the organization, I would like to thank Stefan for his excellent contributions to Sanofi over the years and wish him all the best in his next endeavor.”


 
Sanofi is creating a second new global business unit called China & Emerging Markets to be led by Olivier Charmeil, currently head of the GEM GBU. This newly-formed business will focus on the growth opportunities in emerging markets, particularly in China, which is Sanofi’s second largest market after the U.S. Mr. Charmeil will continue to be a member of the Executive Committee reporting directly to Dr. Brandicourt.


 
Sanofi expects to launch the new Primary Care and China & Emerging Markets global business units by the beginning of 2019. Sanofi’s other GBUs-Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare-remain unchanged.